Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

Simon Fraser University

$48,000.00

A Scalable Synthesis of the C14-C23 Fragment of Eribulin_x000d_ _x000d_

FY 2020-21

Summary
Eribulin, also known as Halaven, is an anticancer drug that has been approved for use in treating pretreated metastatic breast cancer and inoperable liposarcoma. While not itself a natural product, eribulin is a synthetic analogue of the natural product halichondrin, which was originally isolated from a marine sponge. Due to the incredible complexity of the structure of eribulin, its commercial production is one of the most challenging of any approved drug. As a result, there is real interest in identifying improvements to the eribulin synthesis that would ultimately impact the financial and environmental costs of drug production. Towards this goal, the Britton research group at Simon Fraser University has spent several years developing new chemical reactions that enable the rapid and reliable synthesis of tetrahydrofurans, which are small molecules also found in the complicated molecular structure of eribulin. Eurofins-Alphora, a contract research organization located outside of Toronto, has independently spent several years developing a manufacturing route for eribulin. The proposed industry-academic partnership will take advantage of these uniquely aligned interests. Specifically, this collaboration will partner the Britton research groups unique expertise in tetrahydrofuran synthesis with the production capabilities at Eurofins-Alphora to support and improve the large-scale synthesis and commercial production of eribulin. In addition to impacting the various costs of eribulin production, this Canadian academic-industry partnership which is focused on the most complex fully synthetic marketed drug, is an excellent example of innovation and leadership in complex molecule synthesis and will showcase Canada's leading role in this area.
Program
Alliance Grants
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
555427-2020
Name nom
Britton, Robert
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
48000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
A Scalable Synthesis of the C14-C23 Fragment of Eribulin_x000d_ _x000d_
Keyword
NSERC
Application summary
Eribulin, also known as Halaven, is an anticancer drug that has been approved for use in treating pretreated metastatic breast cancer and inoperable liposarcoma. While not itself a natural product, eribulin is a synthetic analogue of the natural product halichondrin, which was originally isolated from a marine sponge. Due to the incredible complexity of the structure of eribulin, its commercial production is one of the most challenging of any approved drug. As a result, there is real interest in identifying improvements to the eribulin synthesis that would ultimately impact the financial and environmental costs of drug production. Towards this goal, the Britton research group at Simon Fraser University has spent several years developing new chemical reactions that enable the rapid and reliable synthesis of tetrahydrofurans, which are small molecules also found in the complicated molecular structure of eribulin. Eurofins-Alphora, a contract research organization located outside of Toronto, has independently spent several years developing a manufacturing route for eribulin. The proposed industry-academic partnership will take advantage of these uniquely aligned interests. Specifically, this collaboration will partner the Britton research groups unique expertise in tetrahydrofuran synthesis with the production capabilities at Eurofins-Alphora to support and improve the large-scale synthesis and commercial production of eribulin. In addition to impacting the various costs of eribulin production, this Canadian academic-industry partnership which is focused on the most complex fully synthetic marketed drug, is an excellent example of innovation and leadership in complex molecule synthesis and will showcase Canada's leading role in this area.